Naoki Okamura, Astellas president and CEO
Astellas bags prostate cancer drug in $175M buyout as Xtandi approaches patent cliff
Astellas is shelling out $175 million in cash to buy Propella Therapeutics and its Phase I prostate cancer therapy that puts a twist on a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
